Boston Scientific Delivers Strong Q3 Earnings: Revenue Up 20%, Full-Year Outlook Raised

Boston Scientific Corp. (BSX) announced strong third-quarter 2025 earnings, exceeding analyst expectations on both revenue and earnings per share. The company’s robust performance was fueled by growth in its Cardiovascular and MedSurg segments, driven by product innovation and expanding global demand. Q3 revenue jumped 20% to $5.07 billion, driven by a strong showing from both the Cardiovascular (up 22.4%) and MedSurg (up 16.4%) segments, with notable U.S. market growth of 27%. While EMEA faced regional challenges, overall performance remained positive.